Broader macroeconomic uncertainty has resulted in continued caution for both investors and acquirers in the in vitro diagnostics sector.

Of the 30 companies included in the list, 24 firms saw their stock prices rise, four saw their share prices decline, and two saw their stock prices remain flat.

The platform will operate at the WA Proteomics Facility, which Proteomics International runs with the University of Western Australia.